90-second daily audio

GLP-1 Daily Brief

FDA actions, supply updates, and trending questions on compounded semaglutide and tirzepatide. Educational only. Not medical advice.

Reviewed by the FormBlends Medical Review Team. Last reviewed April 16, 2026.

What\u2019s in the brief

Each episode runs about 90 seconds and covers three things: any new FDA enforcement actions involving compounded semaglutide, tirzepatide, or peptide-sector pharmacies in the last 24 hours; the most-searched GLP-1 question of the day and a one-sentence answer; and any supply or price movement we\u2019ve spotted in our pharmacy network.

It\u2019s deliberately boring on quiet days. Most days, nothing dramatic happens in GLP-1 regulation. When something breaks (a broad 503A action, a trial readout, a shortage resolution), we\u2019ll run a longer episode and lead with it.

You can subscribe via RSS for your podcast app of choice, or read the transcript on each episode page. Every claim in every transcript links to a named source at the bottom of the page.

How this is made (honest version)

The pipeline runs at 6:00 AM ET daily. A scheduled job pulls the last 24 hours of entries from the FDA enforcement database, queries the Semrush API for movement on GLP-1 search terms, and checks internal supply/price signals. Those inputs get structured into a short prompt.

Claude (Anthropic) drafts a 90-second script from the prompt. The script runs through a compliance filter that checks for banned phrases, equivalency claims, named competitor mentions, and off-label suggestions. A human editor reads the output, fixes anything that slipped through, and approves it for publication. The script is then rendered to audio with our text-to-speech pipeline.

This isn\u2019t a clinician writing a newsletter. It\u2019s AI-generated journalism drawn from public data, reviewed against compliance rules, and published daily. We tell you that here because you deserve to know who\u2019s on the other side of the microphone.

Subscribe via RSS

Episodes

Thursday, April 16, 2026
GLP-1 Daily Brief: April 16, 2026
Here is your GLP-1 daily brief for April 16, 2026. No new FDA enforcement actions targeting compounded semaglutide or tirzepatide were reported in the last 24 hours. The most recent activity from the...
FDA Enforcement DatabaseGLP-1 Index trending data

Frequently asked

Is this medical advice?

No. The brief is journalism, not medicine. It reports on FDA actions, supply updates, and trending questions. It doesn’t tell you what to take, at what dose, or whether something is right for you. That’s a conversation with your clinician.

Who writes the script?

The script is drafted by Claude (Anthropic) from a structured set of inputs: the previous 24 hours of FDA enforcement entries, our GLP-1 Index trending search data, and supply status from our own pharmacy network. A human editor reviews each episode against LegitScript compliance rules before it goes live. There’s no clinician byline on the script because the script isn’t clinician-authored.

Where does the data come from?

FDA enforcement actions come from the FDA public enforcement database, pulled daily. Trending search interest comes from Semrush API queries for GLP-1, semaglutide, tirzepatide, and adjacent terms. Price and supply signals come from FormBlends’ internal pharmacy partners. Each episode lists its named sources at the bottom of the transcript.

How do I subscribe?

The RSS feed is at formblends.com/feed/brief.xml. Paste that into Apple Podcasts, Overcast, Pocket Casts, Spotify (via their podcast submission flow), or any standard podcast app. There’s also a web player on every episode page.

Why 90 seconds?

Because the news cycle around compounded GLP-1s doesn’t need 20 minutes most days. If something major breaks (a broad FDA action, a major trial readout, a supply shock), we’ll run a longer episode. The default is short because most days a FDA inspection log doesn’t deserve a feature segment.